CONFLICT OF INTEREST STATEMENT
TBC, Stock
TBC
TBC: Honoraria, consultancy fees or research funding from AstraZeneca, Bayer, Eli Lilly, Genentech/Roche, Bristol Myers Squibb, Merck and Merck Sharp & Dohme. FC, AFI, and JA: Stock in and honoraria from Autem Therapeutics and patents relating to the AutEMdev. YdCS: Honoraria from Bayer, Merck and Novartis and independent contractor at Hospital Sirio‐Libanês. GKA‐A: Institutional research support from Arcus, Astra Zeneca, BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Silenseed, Yiviva; consulting fees from Adicet, Alnylam, Astra Zeneca, Autem, Beigene, Berry Genomics, Boehringer Ingelheim, Celgene, Cend, CytomX, Eisai, Eli Lilly, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Helsinn, Incyte, Ipsen, Merck, Nerviano, Newbridge, Novartis, QED, Redhill, Rafael, Servier, Silenseed, Sobi, Vector, Yiviva; registered patent: PCT/US2014/031545 filed on March 24, 2014, and priority application Serial No.: 61/804,907; Filed: March 25, 2013. DLJ honoraria, consultancy fees or research funding from AstraZeneca, Bayer, Janssen, Astellas, Genentech/Roche, Bristol Myers Squibb, Merck and Merck Sharp & Dohme.